 GSK2330811 is a humanised monoclonal antibody, that blocks Oncostatin M OSM, which is being developed for the treatment of inflammatory and fibrotic diseases. This first time in human study will evaluate the safety, tolerability, pharmacokinetic PK, pharmacodynamic PD and immunogenicity profile of single ascending subcutaneous s.c. doses of GSK2330811, in healthy subjects. 